Hanmi Pharmaceutical Q1 Operating Profit Falls 9.1% as China Unit Doubles, Holding Co. Climbs 24%

TL;DR - Hanmi Pharmaceutical posted Q1 2026 operating profit of ₩53.6 billion ($39 million), down 9.1% year-on-year against a tough partner-supply base. - Beijing Hanmi operating profit more than doubled to ₩23.6 billion ($17 million), and parent Hanmi Science grew operating profit 24% to ₩33.6 billion ($25 million). - Watch H2 2026 for a domestic regulatory decision on obesity drug efpeglenatide, the first internal launch catalyst since the 2025 Merck clinical-sample base effect faded.

Lead

Hanmi Pharmaceutical (128940.KS), Korea's eighth-consecutive-year leader in domestic outpatient prescriptions, reported on April 30 that first-quarter consolidated operating profit fell 9.1% year-on-year to ₩53.6 billion ($39 million), even as revenue edged up 0.5% to ₩392.9 billion ($287 million). A company official attributed the operating-profit decline to a one-time base effect from prior-year clinical-sample shipments to Merck (known as MSD outside the U.S. and Canada) for the efinopegdutide MASH program, per Seoul Economic Daily. The result lands as the company prepares to commercialize its proprietary GLP-1 obesity drug efpeglenatide later this year.

What Happened

In its preliminary Q1 disclosure on the Korea Exchange, Hanmi Pharmaceutical reported revenue of ₩392.9 billion ($287 million), operating profit of ₩53.6 billion ($39 million), and net profit of ₩51.1 billion ($37 million), up 14.4% year-on-year, according to Yonhap and Seoul Economic Daily. The company said R&D spending reached ₩65.2 billion ($48 million) in the quarter, equivalent to 16.6% of revenue, per Seoul Economic Daily.

Domestic outpatient prescription revenue, tracked by industry data provider UBIST, totaled ₩277.6 billion ($203 million), Chosun Biz reported. Within that pool:

• Rosuzet, the company's dyslipidemia combination therapy, generated ₩59.3 billion ($43 million), up 9.2% year-on-year.
• The Amosartan family of hypertension treatments delivered ₩36.4 billion ($27 million), per Chosun Biz.
• The Esomezol family of acid-reflux drugs added ₩14.6 billion ($11 million), per Chosun Biz.

China subsidiary Beijing Hanmi Pharmaceutical posted Q1 revenue of ₩106.4 billion ($78 million), up 10.3% year-on-year, with operating profit jumping 107.7% to ₩23.6 billion ($17 million); the company credited an inventory-destocking tailwind in the Chinese channel, according to Chosun Biz. Active pharmaceutical ingredient affiliate Hanmi Fine Chemical reported Q1 revenue of ₩21.7 billion ($16 million) and swung back into operating profit, helped by contract development and manufacturing (CDMO) order growth that offset antibiotics-market price pressure.

Separately, listed holding company Hanmi Science reported Q1 operating profit of ₩33.6 billion ($25 million), up 24% year-on-year, on revenue of ₩353.7 billion ($258 million), up 6.5%, according to local press reporting. Hanmi Science attributed the gain to broad-based contributions across group affiliates, including its Online Pharm pharmaceutical-distribution arm.

Why It Matters

The quarter is the first concrete signal that Hanmi's underlying operating engine — domestic chronic-disease franchises plus a recovering China unit — can absorb the loss of one-time partner-supply revenue without breaking margin discipline. Stripping out the prior-year base effect highlighted by management, the cash-generative core (Rosuzet up 9.2%, Beijing Hanmi operating profit up 107.7%) continued to expand even as headline operating profit declined. With R&D running at 16.6% of revenue, the spending intensity behind the company's late-stage obesity pipeline is being funded from current operations rather than from non-recurring milestone income — a structural shift in the earnings mix that matters as efpeglenatide approaches a domestic launch decision.

Business Impact

For the operating company, the largest near-term swing factor is Beijing Hanmi, where the Q1 operating-margin step-up reflects channel destocking that management has flagged as a tailwind. Sustained China contribution would offset the higher base of one-off domestic licensing income that flattered the year-ago comparison.

For the holding company, Hanmi Science's 24% operating-profit growth and 6.5% revenue growth indicate that the non-pharmaceutical layer of the group — primarily the Online Pharm B2B distribution business and group healthcare units — is now contributing materially to consolidated profit. That broadens the cash base available to fund the company-wide efpeglenatide commercialization task force the group activated on April 13, 2026, according to Seoul Economic Daily.

For the late-stage pipeline, CEO Hwang Sang-yeon framed 2026 as a year of clinical milestones, telling reporters that "this year is expected to be an important one in which we will see clinical progress in various new drug development areas," as quoted by Seoul Economic Daily. Hanmi has filed efpeglenatide with the MFDS (Korea's Ministry of Food and Drug Safety) and has signed an exclusive Mexico distribution agreement with Laboratorios Sanfer, per Seoul Economic Daily reporting on the company's January 28 announcement.

Industry & Historical Context

Hanmi's quarter sits inside a broader Korean drugmaker re-rating tied to obesity-pipeline catalysts. Seoul Economic Daily reported on May 2 that Korean pharmaceutical companies are heading into the second half with multiple late-stage readouts, of which Hanmi's efpeglenatide is among the most watched domestic-launch candidates. Efpeglenatide was originally licensed to Sanofi in 2015 before being returned to Hanmi following a strategic shift at the partner; the asset is now being developed in-house using Hanmi's proprietary LAPSCOVERY long-acting platform, with Phase 3 data showing cardiovascular protection benefits, according to Seoul Economic Daily's coverage of the April 13 task-force launch.

The Q1 operating-profit decline against a high base also follows a 2024 in which Hanmi posted record revenue, per Korea Biomedical Review, meaning the year-on-year comparison is being made against an unusually strong reference period rather than against a deteriorating trend. Hanmi has held the No. 1 position in Korea's domestic outpatient prescription market for eight consecutive years, since 2018, according to Seoul Economic Daily.

What to Watch

• MFDS decision on efpeglenatide. Approval is targeted within 2026, with obesity indication first and a diabetes indication planned for 2028, per Seoul Economic Daily and Korea Biomedical Review.
• Beijing Hanmi sustainability. Whether the 107.7% Q1 operating-profit jump persists once the Chinese channel destocking effect normalizes.
• R&D-to-revenue trajectory. Hanmi spent 16.6% of Q1 revenue on R&D sustained spending at this level into a launch year tests how much of the obesity launch the company funds internally versus through partnerships.
• Hanmi Science contribution mix. Holding-company Q1 growth was driven by Online Pharm and group healthcare; continued contribution would lessen reliance on milestone income from licensing deals.

Sources: - Yonhap News Agency — https://www.yna.co.kr/view/AKR20260430162300527 - Chosun Biz — https://biz.chosun.com/science-chosun/bio/2026/04/30/NTMU7S66NJDXPGUMBT22S2LGMI/ - Seoul Economic Daily (Q1 results) — https://en.sedaily.com/finance/2026/04/30/hanmi-pharmaceutical-q1-operating-profit-falls-91-percent - Seoul Economic Daily (efpeglenatide task force) — https://en.sedaily.com/finance/2026/04/17/hanmi-pharmaceutical-launches-commercialization-task-force - Seoul Economic Daily (sector outlook) — https://en.sedaily.com/business/2026/05/02/korean-drugmakers-eye-h2-pipeline-catalysts-after-q1 - Korea Biomedical Review (2024 record revenue) — https://www.koreabiomed.com/news/articleView.html?idxno=25786 - Korea Biomedical Review (Q1 2025 base context) — https://www.koreabiomed.com/news/articleView.html?idxno=27435

By LineVest Markets Desk — April 30, 2026

This article is for informational purposes only and does not constitute investment advice.